# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.46)...
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.
Globe Newswire- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatme...
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mu...
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company r...
Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues des...